Isomorphic Labs
isomorphiclabs.com
AI drug discovery company from DeepMind.
Quick Information
- Category:
- Healthcare
- Pricing:
- Contact Sales
- Platforms:
- Cloud
- Free Plan:
- No
- API Available:
- No
- Last Verified:
- October 2026
What Is Isomorphic Labs?
Isomorphic Labs is an AI drug discovery company that grew out of Google DeepMind. Its core product is IsoDDE, the Isomorphic Drug Design Engine, which builds on AlphaFold 3, the biomolecule structure prediction model that DeepMind and Isomorphic released in May 2024. The company does not sell software. It works with large drugmakers and develops its own programs.
Funding has been huge. In May 2026 it reported a $2.1 billion Series B led by Thrive Capital, with Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund taking part. One report says it is now in talks at a valuation of at least $40 billion, which is unconfirmed. In January 2024 it signed deals with Eli Lilly, with $45 million upfront and up to about $1.7 billion in milestones, and Novartis, with $37.5 million upfront and up to $1.2 billion, and Novartis later expanded its collaboration. One source also lists Johnson & Johnson as a partner, but that was not corroborated. Importantly, Isomorphic has not released clinical data or dosed a patient, and plans first-in-human trials by the end of 2026.
Isomorphic suits pharma companies and investors who want exposure to frontier AI drug design. Compare Insilico Medicine, Recursion and Schrödinger. Browse the Healthcare tools directory for more.
What Can You Use Isomorphic Labs For?
AI drug design
IsoDDE designs candidate molecules.
Pharma collaborations
Works with Eli Lilly and Novartis.
Internal pipeline
Plans first-in-human trials by end of 2026.
Isomorphic Labs Features
- IsoDDE — Isomorphic Drug Design Engine built on AlphaFold 3.
- Large partnerships — Lilly and Novartis deals worth billions in milestones.
- DeepMind heritage — Spun out from Google DeepMind's research.
- Heavy funding — $2.1B Series B in May 2026.
Who Is Isomorphic Labs For?
- Large pharma — Partner on difficult targets.
- Investors and researchers — Follow the next generation of AI drug design.
Isomorphic Labs Pros & Limitations
What We Like
- Backed by AlphaFold technology
- Large, well-known pharma partners
- Exceptional funding
Limitations
- No clinical data or dosed patients yet
- Not a product you can buy
- Valuation reports are unconfirmed
Isomorphic Labs Pricing
| Plan | Price | Main Features |
|---|---|---|
| Pharma partnerships | Deal-based; upfronts of $37.5M to $45M reported for Novartis and Lilly | Collaborations on drug targets with milestone payments |
Pricing was last verified October 2026. Check the official website for the latest pricing.
AI Listing Jungle Ranking
- Global Rank:
- #860
- Overall Score:
- 48.6/100
- Monthly Users:
- –
- Rank Change:
- ▼ 223
This ranking reflects AI Listing Jungle's own independent scoring methodology and is not an endorsement by Isomorphic Labs or its company. How Our Rankings Work
Frequently Asked Questions
What is Isomorphic Labs?
An AI drug discovery company spun out of Google DeepMind.
How much did it raise?
A $2.1 billion Series B in May 2026 led by Thrive Capital.
Which pharma companies work with it?
Eli Lilly and Novartis, with Johnson & Johnson reported by one unconfirmed source.
Has it tested drugs in people?
No, it plans first-in-human trials by the end of 2026.
Our Take
Isomorphic has the technology pedigree and the money, but its value will be decided in the clinic.
It is a platform for partners rather than a tool for individual researchers.
Isomorphic Labs Alternatives
Isomorphic Labs Comparisons
Ready to try Isomorphic Labs?
Visit the official website to get started.
Visit Official WebsiteAI Listing Jungle is an independent AI tools directory. Product names, logos, and trademarks belong to their respective owners.